Literature DB >> 3398729

Magnetic resonance imaging of soft tissue masses: an evaluation of fifty-three histologically proven tumors.

M Sundaram1, M H McGuire, D R Herbold.   

Abstract

Fifty-three histologically confirmed soft tissue masses in 48 patients were evaluated by magnetic resonance imaging (MR) and computerized tomography (CT). Twenty-three of these were malignant, twenty-three benign and seven of intermediate malignancy (all aggressive fibromatosis). The two procedures were compared for sensitivity and delineation of masses, their relationship to important neurovascular structures, their potential for histological diagnoses, their relative roles in influencing the surgical approach and the preferred modality in the follow-up for detection of tumor recurrence. Both modalities have their relative strengths and weaknesses. However, the superior contrast resolution of magnetic resonance imaging, its demonstration of lesions not clearly identified by CT, its pluridirectional capabilities and its ability to demonstrate large soft tissue tumors in a single coronal or sagittal plane makes it the preferred initial modality for evaluation of the soft tissue tumor of uncertain etiology and also in the follow-up of these patients. Despite MR's superiority in anatomically staging soft tissue tumors it, like CT, is of limited value in characterizing soft tissue sarcomas.

Entities:  

Mesh:

Year:  1988        PMID: 3398729     DOI: 10.1016/0730-725x(88)90397-9

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  19 in total

1.  FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.

Authors:  J Aoki; H Watanabe; T Shinozaki; K Takagishi; M Tokunaga; Y Koyama; N Sato; K Endo
Journal:  Skeletal Radiol       Date:  2003-01-24       Impact factor: 2.199

Review 2.  Soft-tissue masses in the shoulder girdle: an imaging perspective.

Authors:  Srinivasan Harish; Asif Saifuddin; Philip W P Bearcroft
Journal:  Eur Radiol       Date:  2006-04-25       Impact factor: 5.315

3.  MRI texture analysis predicts p53 status in head and neck squamous cell carcinoma.

Authors:  M Dang; J T Lysack; T Wu; T W Matthews; S P Chandarana; N T Brockton; P Bose; G Bansal; H Cheng; J R Mitchell; J C Dort
Journal:  AJNR Am J Neuroradiol       Date:  2014-09-25       Impact factor: 3.825

4.  Giant atypical ossifying fibromyxoid tumour of the calf.

Authors:  Srinivasan Harish; Alexander Polson; Paul Morris; Charles Malata; Meryl Griffiths; Philip W P Bearcroft
Journal:  Skeletal Radiol       Date:  2005-09-24       Impact factor: 2.199

5.  MRI of malignant fibrous histiocytoma of soft tissue: analysis of 13 cases with pathologic correlation.

Authors:  T T Miller; G Hermann; I F Abdelwahab; M J Klein; S Kenan; M M Lewis
Journal:  Skeletal Radiol       Date:  1994-05       Impact factor: 2.199

6.  Imaging of congenital esophageal cysts in adults.

Authors:  S Bondestam; J A Salo; O L Salonen; A E Lamminen
Journal:  Gastrointest Radiol       Date:  1990

7.  Case report 829: Intramuscular myxoid chondrosarcoma.

Authors:  C G Whitten; G Y el-Khoury; J A Benda; S Ehara
Journal:  Skeletal Radiol       Date:  1994-02       Impact factor: 2.199

8.  Magnetic resonance appearance of peripheral nerve sheath tumors.

Authors:  M A Stull; R P Moser; M J Kransdorf; G P Bogumill; M C Nelson
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

9.  Musculoskeletal magnetic resonance imaging: importance of radiography.

Authors:  Mihra S Taljanovic; Tim B Hunter; Kimberly A Fitzpatrick; Elizabeth A Krupinski; Thomas L Pope
Journal:  Skeletal Radiol       Date:  2003-06-03       Impact factor: 2.199

10.  The value of intratumoral heterogeneity of (18)F-FDG uptake to differentiate between primary benign and malignant musculoskeletal tumours on PET/CT.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Megumi Jinguji; Yoshihiko Fukukura; Yoshiaki Nakabeppu; Atsushi Tani; Takashi Yoshiura
Journal:  Br J Radiol       Date:  2015-09-04       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.